Details werden geladen...
Lira Clinical Announces New REGEN Line - A First-of-Its-Kind Breakthrough in Regenerative Skincare | The Manila Times
LIVERMORE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Lira Clinical, a global leader in corrective and brightening skincare, is proud to announce the launch of its groundbreaking new REGEN line. REGEN is the first and only clinical skincare line formulated with Wild Salmon Stem Cell-Conditioned Media - a revolutionary ingredient that delivers 4 times more regenerative power than PDRN alone.
Ähnliche Seiten
Researcher Announces "Two Sides of the Gravity Coin” Breakthrough in New SP3 Physics Paper | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/plentisoft/researcher-announces-two-sides-of-the-gravity-coin-breakthrough-in-new-sp3-physics-paper/2345816
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform | The Manila Times
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/biorestorative-therapies-announces-completion-of-brtx-100-phase-2-manufacturing-highlighting-integrated-regenerative-biologics-platform/2372834Kraig Biocraft Laboratories Announces Breakthrough Creation of Immortalized Silkworm Silk Gland Cell Line with Broad Biotechnology Applications | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/kraig-biocraft-laboratories-announces-breakthrough-creation-of-immortalized-silkworm-silk-gland-cell-line-with-broad-biotechnology-applications/2346103Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/lynk-pharmaceuticals-announces-first-patient-dosed-in-phase-ii-clinical-trial-of-lnk01004-ointment-for-vitiligo/2381288Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1 | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811